HI
NKTR icon

Harbour Investments’s Nektar Therapeutics NKTR Stock Holding History

Harbour Investments’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10
Closed -$569 – 3970
2025
Q3 		$569 Hold
10
– – ﹤0.01% 3494
2025
Q2 		$258 Hold
10
– – ﹤0.01% 3452
2025
Q1 		$105 Hold
10
– – ﹤0.01% 3472
2024
Q4 		$144 Hold
10
– – ﹤0.01% 3385
2024
Q3 		$202 Hold
10
– – ﹤0.01% 3277
2024
Q2 		$192 Hold
10
– – ﹤0.01% 3165
2024
Q1 		$145 Hold
10
– – ﹤0.01% 3134
2023
Q4 		$88 Hold
10
– – ﹤0.01% 3059
2023
Q3 		$92 Hold
10
– – ﹤0.01% 2929
2023
Q2 		$89 Hold
10
– – ﹤0.01% 2955
2023
Q1 		$109 Hold
10
– – ﹤0.01% 2918
2022
Q4 		$350 Hold
10
– – ﹤0.01% 2829
2022
Q3 		$1K Hold
10
– – ﹤0.01% 2621
2022
Q2 		$1K Buy
+10
New +$631 ﹤0.01% 2621
2021
Q4 		$2K Sell
10
-11
-52% -$2.39K ﹤0.01% 2414
2021
Q3 		$6K Hold
21
– – ﹤0.01% 2910
2021
Q2 		$5K Hold
21
– – ﹤0.01% 3064
2021
Q1 		$6K Buy
+21
New +$6.54K ﹤0.01% 2845

Other funds holding NKTR

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Harbour Investments's NKTR Position: Q4 2025 in Review

Harbour Investments sold out of Nektar Therapeutics (NKTR) in Q4 2025, closing a stake of 10 shares — an estimated $569 sold.

Harbour Investments first reported a position in NKTR in Q1 2021 and held it in 18 quarters. The position peaked at $6K in Q3 2021. 180 funds tracked by Wall St. Rank hold NKTR as of Q4 2025.

  • Harbour Investments reported no remaining Nektar Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Harbour Investments sold 10 Nektar Therapeutics shares in Q4 2025, an estimated $569.
  • Harbour Investments first reported a position in Nektar Therapeutics in Q1 2021 and held it in 18 quarters.
  • Harbour Investments's Nektar Therapeutics position peaked at $6K in Q3 2021.
  • 180 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2025.

Based on Harbour Investments's 13F filing for Q4 2025, filed 9 Feb 2026.